New Weight-Loss drug candidate enters first human tests
NCT ID NCT07487376
First seen Apr 08, 2026 · Last updated May 23, 2026 · Updated 6 times
Summary
This early-stage study tests a single dose of the experimental drug IBIO-600 in 32 overweight or obese adults. The main goal is to find a dose that is safe and well-tolerated, while also checking how the drug affects body composition. Participants must be in good general health with a stable weight and a BMI between 27 and 34.9.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT , OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Veritus Research
Bayswater, Victoria, 3153, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.